Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Monte Rosa Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $170.69M, up 32.0% year over year. For fiscal 2025 it was $141.50M, up 16.4% from the year before. The highest annual figure on record is $141.50M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.50M | +16.4% |
| FY2024 | Dec 31, 2024 | $121.56M | +9.2% |
| FY2023 | Dec 31, 2023 | $111.27M | +30.8% |
| FY2022 | Dec 31, 2022 | $85.06M | +48.8% |
| FY2021 | Dec 31, 2021 | $57.16M | +138.1% |
| FY2020 | Dec 31, 2020 | $24.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $47.96M | +56.5% |
| Q1 FY2026 | Mar 31, 2026 | $44.07M | +36.9% |
| Q4 FY2025 | Dec 31, 2025 | $41.98M | +8.0% |
| Q3 FY2025 | Sep 30, 2025 | $36.68M | +32.8% |
| Q2 FY2025 | Jun 30, 2025 | $30.65M | +9.3% |
| Q1 FY2025 | Mar 31, 2025 | $32.19M | +19.1% |
| Q4 FY2024 | Dec 31, 2024 | $38.87M | +43.2% |
| Q3 FY2024 | Sep 30, 2024 | $27.62M | -2.4% |
| Q2 FY2024 | Jun 30, 2024 | $28.06M | -3.5% |
| Q1 FY2024 | Mar 31, 2024 | $27.03M | +1.0% |
| Q4 FY2023 | Dec 31, 2023 | $27.14M | +9.1% |
| Q3 FY2023 | Sep 30, 2023 | $28.31M | +32.6% |
| Q2 FY2023 | Jun 30, 2023 | $29.08M | +38.9% |
| Q1 FY2023 | Mar 31, 2023 | $26.76M | +49.3% |
| Q4 FY2022 | Dec 31, 2022 | $24.87M | +37.2% |
| Q3 FY2022 | Sep 30, 2022 | $21.34M | +41.2% |
| Q2 FY2022 | Jun 30, 2022 | $20.94M | +43.0% |
| Q1 FY2022 | Mar 31, 2022 | $17.92M | +93.2% |
| Q4 FY2021 | Dec 31, 2021 | $18.13M | +83.8% |
| Q3 FY2021 | Sep 30, 2021 | $15.12M | +176.2% |
| Q2 FY2021 | Jun 30, 2021 | $14.64M | +201.5% |
| Q1 FY2021 | Mar 31, 2021 | $9.27M | – |
| Q4 FY2020 | Dec 31, 2020 | $9.86M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.47M | – |
| Q2 FY2020 | Jun 30, 2020 | $4.86M | – |
See a number that looks wrong?